ClinConnect ClinConnect Logo
Search / Trial NCT05745610

Shen Hai Long Capsule for Male Asthenospermia

Launched by ZHONGNAN HOSPITAL · Feb 15, 2023

Trial Information

Current as of September 07, 2025

Unknown status

Keywords

Efficacy Safety

ClinConnect Summary

To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men: 1) Efficacy index (1) Main efficacy indexes Forward motile sperm ratio (PR) (2) Secondary efficacy indexes 1. Sperm survival rate; 2. Sperm concentration; 3. Normal morphology rate of sperm; 4. Seminal malondialdehyde (MDA) 5. Seminal superoxide dismutase (SOD) 2) Safety indicators

(1) Vital signs; (2) liver and kidney function; (3) blood routine; (4) electrocardiogram; (5) Adverse events.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age range from 22 to 50 years old;
  • 2. Patients with mild to moderate asthenospermia, that is, at least two normative semen analyses indicated that 10%≤PR percentage \< 32% and the total number of PR sperm ranged from 5 million to 20 million;
  • 3. At least two standard semen analyses indicated that sperm concentration ≥15×106 /ml; Sperm normal morphology rate ≥4%;
  • 4. No other Chinese and Western drugs for the treatment of oligospermia, weak and malformed spermia have been taken in the past 3 months;
  • 5. The subject voluntarily participates and signs the informed consent.
  • Exclusion Criteria:
  • 1. Varicocele, ejaculatory duct/seminal vesicle cyst, anti-sperm antibody (+);
  • 2. Genital tract infection: seminal plasmic elastase \> 1000ng/ml or leukocyte semen disease (peroxidase positive cell concentration in semen more than 1×10\^6/mL);
  • 3. Erectile dysfunction, ejaculation disorders;
  • 4. suffer from mental disorders, immune system diseases; Severe impairment of liver and kidney function (serum transaminase ≥2× upper limit of medical reference value, creatinine clearance ≤40ml/min or active stage of chronic kidney disease);
  • 5. Patients with allergic history or constitution to therapeutic drugs;
  • 6. Patients who have taken drugs affecting the study within 3 months, such as antitumor and antiepileptic drugs, etc.

About Zhongnan Hospital

Zhongnan Hospital, affiliated with Wuhan University, is a leading medical institution in China renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on multidisciplinary collaboration, the hospital employs state-of-the-art facilities and a team of highly skilled professionals to conduct rigorous clinical studies aimed at improving patient outcomes. Zhongnan Hospital prioritizes ethical standards and patient safety, ensuring adherence to regulatory requirements while fostering a culture of scientific excellence. As a prominent sponsor of clinical trials, the hospital plays a pivotal role in contributing to the global medical community and enhancing the understanding of various health conditions.

Locations

Wuhan, Hubei, China

Wuhan, , China

Patients applied

0 patients applied

Trial Officials

Yuanzhen Zhang, Prof.

Principal Investigator

Wuhan University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials